Expert witness in drug design and medicinal chemistry: Lemont Kier Ph.D.

Lemont Kier

	Professor Lemont Kier is considered one of the leading chemists in the field of advanced drug design. For his work in medicinal chemistry, Professor Kier was awarded the 2008 American Association of Pharmaceutical Research Achievement Award.

The author of seven textbooks and over 250 research articles, Professor Lemont Kier introduced the use of molecular orbital theory to compute the preferred conformation of molecules, participated in the early development of drug design from a random search-and-formulate approach into model building activity before actually creating the molecule. He has published the first paper in which a three-dimensional model of a chemical transmitter in the central nervous system was predicted, and has also developed the current theory for defining molecules with a sweet taste. In the early 1990's, he and a colleague developed a method that drug companies use to evaluate databases to find similar compounds. Professor Kier has also been a leader in the development of the theory of the interaction of general anesthetic gases with the body. With his down-to-earth demeanor, Professor Lemont Kier,"Monty", enjoys explaining complicated chemical processes in a manner that helps specialists advance and non-specialists understand. He consults world-wide as an expert witness, scientific adviser, and researcher through <a target="_parent"href="../">Rubin/Anders Scientific</a>. <h2>Areas of Expertise</h2> Lamont Kier Can Provide Hands-On Professional Expertise and expert testimony in the following areas: <ul class="horizList"> <li>Adverse Drug Reaction, </li> <li>Anesthetic Gases, </li> <li>Anticonvulsants, </li> <li>Applied Organic Chemistry, </li> <li>Biochemistry, </li> <li>Bioorganic Chemistry, </li> <li>Biophysical Chemistry, </li> <li>Biotechnology, </li> <li>Cellular Automata Studies, </li> <li>Chemical Pharmacology, </li> <li>Chemical Structure and Bonding, </li> <li>Chemical Transmitters, </li> <li>Clinical Chemistry, </li> <li>Clinical Trials, </li> <li>Complexity and Emergence, </li> <li>Computational Chemistry Diuretics, </li> <li>Drug Bioavailability, </li> <li>Drug Design, </li> <li>Drug Development, </li> <li>Drug Discovery, </li> <li>Drug Metabolism, </li> <li>Drug Receptor Interactions, </li> <li>Drug Synthesis and Development, </li> <li>Drug Therapy, </li> <li>Drug Toxicology, </li> <li>Drug-Receptor Interactions, </li> <li>Electrotopological State Descriptors, </li> <li>Expert In Pharmaceutical Product Development, </li> <li>General Anesthetics, </li> <li>Hypnotics, </li> <li>Immunocytochemistry, </li> <li>Kappa Shape and Flexibility Descriptors, </li> <li>Laboratory Diagnostics, </li> <li>Lipid Biochemistry, </li> <li>Medicinal Chemistry, </li> <li>Molecular Connectivity Descriptors, </li> <li>Molecular Orbital Theory, </li> <li>Molecular Pharmacology, </li> <li>Nsaids, </li> <li>Opioid Analgesics, </li> <li>Organic Synthesis, </li> <li>Pharmaceutical and Chemical Analyses, </li> <li>Pharmaceutical Chemistry, </li> <li>Pharmaceutical Product Development, </li> <li>Pharmaceuticals, </li> <li>Pharmacokinetics, </li> <li>Physical Property Descriptors, </li> <li>Principals Of Drug Design, </li> <li>Protein Binding, </li> <li>Peptide Binding, </li> <li>Quantum Pharmacology, </li> <li>Sedatives, </li> <li>Small Molecules For Medicinal Chemistry, </li> <li>Small Molecule Drugs, </li> <li>Structure-Activity Concepts, </li> <li>Structure Activity Relationships (Sars), </li> <li>and Synthetic Organic Chemistry.</li> </ul>